Results 251 to 260 of about 98,500 (300)

Testing the Broad Definition of Pre‐Eclampsia: Should Chronic Hypertension With Fetal Growth Restriction Be Included?

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
Peter von Dadelszen, Terry Lee, Joel Singer, Laura A. Magee, For the CHIPS Study Group   +4 more
wiley   +1 more source

Melioidosis in companion animals: Analysis of 45 Australian cases (24 dogs; 21 cats) from 1997 to 2025 and a brief review of the animal and human literature

Australian Veterinary Journal, EarlyView.
Objective To report 45 cases of melioidosis in dogs and cats from northern Australia and analyse trends in epidemiology, clinical presentation, pathogenesis and response to treatment over a 27‐year period. Design Retrospective and prospective analysis of clinical records.
K Lee, C Shilton, S Benedict, M Krockenberger, M Mayo, BJ Currie, R Malik   +6 more
wiley   +1 more source

Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria. [PDF]

J Pers Med
Checa-Ros A, Okojie OJ, Wassouf JG, Yedean A, Hsueh WC, Hebda P, Llobell ER, Muhmenthaler GB, Tran MD, D'Marco L.   +9 more
europepmc   +1 more source

Association between albuminuria and arterial stiffness measured by brachial-ankle pulse wave velocity among Chinese population: A retrospective study. [PDF]

Medicine (Baltimore)
Yeh WC, Li WC, Wang MW, Hsu CW, Tsao YC, Lin YH, Chen JY.   +6 more
europepmc   +1 more source

Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study

British Journal of Haematology, EarlyView.
Renal dysfunction represents a possible underrecognized complication of symptomatic WM; this condition correlates with adverse global and disease‐specific clinical outcomes. Summary The prognostic significance of impaired renal function in Waldenström macroglobulinaemia (WM) remains poorly defined.
Nicolò Danesin, Francesco Autore, Anna Maria Frustaci, Gianmarco Favrin, Emanuele Cencini, Alessandro Noto, Irene Dogliotti, Jacopo Olivieri, Marcello Riva, Isacco Ferrarini, Anna Maria Barbui, Sara Steffanoni, Dario Marino, Benedetta Puccini, Piero Maria Stefani, Rita Rizzi, Michele Merli, Angela Ferrari, Stefano Luminari, Carlo Visco, Livio Trentin, Andrea Visentin, Annarita Conconi, Simone Ferrero, Marzia Varettoni, Alessandra Tedeschi, Luca Laurenti, Francesco Piazza   +27 more
wiley   +1 more source

Analysis of Circulating and Urinary Levels of hsa-miRNA-770-5p in Diabetic Nephropathy. [PDF]

Biomolecules
Nikolov D, Nikolov G, Geneva-Popova M, Popova-Belova S, Naydenov M, Karusheva MG.   +5 more
europepmc   +1 more source

Daratumumab plus bortezomib and dexamethasone (Dara‐VD) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study

British Journal of Haematology, EarlyView.
Summary Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a ...
Gao Xue‐min, Xu Chengyang, Gao Ya‐juan, Guan Ai, Xu Yi, Chang Long, Shen Kai‐ni, Li Jian   +7 more
wiley   +1 more source

Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial. [PDF]

World J Nephrol
Arnedo RD, Polo VS, Garcia JB, Gutiérrez JF, Clason ER, Domínguez D, Rebutti GM, Mancia CM, López RT, Meza MR, López DT, Muñoz Zambrano JJ, Herrera EL, Dina-Batlle E, Terrones MC, de Moraes TP, Yánez TR, Osorio W, Cabeza AA, Rico-Fontalvo J.   +19 more
europepmc   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

British Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source